Article

Long-term safety and efficacy of COVE study open-label and booster phases

2024-03-14

Abstract excerpt

<title>Abstract</title> <p>Vaccination with two injections of mRNA-1273 (100-μg) was shown to be safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the Coronavirus Efficacy (COVE) trial at completion of the blinded part of the study. We present the final report of the longer-term safety and efficacy data of the primary vaccination series plus a 50-μg booster dose administered in Fall 2021....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9fbbb44e-dd6f-59c5-ae24-16a05ba0e88c
DOI: 10.21203/rs.3.rs-3900939/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-term safety and efficacy of COVE study open-label and booster phasesDOI 10.21203/rs.3.rs-3900939/v1Read

Effectiveness of Mrna Booster Vaccination Against Mild and Severe COVID-19 During Delta and Omicron Variant Circulation in Germany: An Analysis of National Surveillance DataSemantic proximity Read

COVID‐19 Vaccine Efficacy and the Evidence on BoostersSemantic proximity Read

COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial Evidence on the Omicron Variant)Semantic proximity Read

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscapeSemantic proximity Read

Comparative effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections: A time-varying cohort analysis using trial emulation in the Virus Watch community cohortSemantic proximity Read

Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)Semantic proximity Read

Reported Effectiveness of COVID-19 Booster Vaccines: A Systematic Review of Early Literature and Implications for Emerging Vaccination PolicySemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

Comparative effectiveness of BNT162b2 versus mRNA-1273 boosting in England: a cohort study in OpenSAFELY-TPPSemantic proximity Read

Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)Semantic proximity Read

Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United StatesSemantic proximity Read

Antibody Response After COVID-19 mRNA Vaccination in Relation to Age, Sex, and Side EffectsSemantic proximity Read